Human lens cholesterol concentrations in patients who used lovastatin or simvastatin

Archives of Ophthalmology

Volumn 117, Issue 5, 1999, Pages 653-657

  Mitchdl, Jefliine ^a,b   Ceneddla, Richard J ^b  

^a TRUMAN STATE UNIVERSITY   (United States)

^b A T STILL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN TISSUE; LENS; LIPID ANALYSIS; LIPID COMPOSITION; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0032917456     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.5.653     Document Type: Article

References (25)

1. Zelenka PS. Lens lipids. CurrEye Res. 1984:3:1337-1359.
2. Li LK, So L, Spector A. Membrane cholesterol and phospholipid in consecutive concentric sections of human lenses. J Lipid Res. 1985:26:600-609.
3. Borchman D, Cenedella RJ, Lamba OP. Role of cholesterol in the structural order of lens membrane lipids. Exp Eye Res. 1996:62:191-198.
4. Tang D, Borchman D, Yappert MC, Cenedella RJ. Influence of cholesterol on the interaction of a-crystallin with phospholipids. Exp Eye Res. 1998:66:559-567.
5. Cenedella RJ. Sterol synthesis by the ocular lens of the rat during postnatal development. JLipid Res. 1982:23:619-626.
6. deVries ACJ, Vermeer MA, Bredman JJ, Bar PR, Cohen LH. Cholesterof content of the rat lens is lowered by administration of simvastatin, but not by pravastatin. Exp Eye Res. 1993:56:393-399.
7. Kirby TJ, Achor RWP, Perry HO, Winkelmann RK. Cataract formation after triparanol therapy. Arch Ophthalmol. 1962:68:486-489.
8. Laughlin RC, Carey TF. Cataracts in patients treated with triparanol. JAMA. 1962; 181:339-340.
9. Avigan J, Steinberg D, Vroman HE, et al. Studies of cholesterol biosynthesis, I: the identification of desmosterol in serum and tissues of animals and men with Mer29. JBiolChem. 1960:235:3123-3129.
10. von Sallmann L. Triparanol-induced cataracts in rats. Trans Am Ophthalmol Soc. 1963:61:49-60.
11. Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 1990:50:65-78.
12. Mölgaard J, Lundn EL, von Schenck H, Olsson AG. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholsterolemia. Atherosclerosis. 1991;91(suppl):S21-S28.
13. Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol. 1996:40:320-337.
14. Mosley ST, Kalinowski SS, Schafer BL, Tanaka RD. Tissue selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. JLipid Res. 1989:30:1411-1420.
15. Rafferty MS. Lens morphology. In: Maisei H, ed. The Ocular Lens: Structure, Function and Pathology. New York, NY: Marcel Dekker Inc; 1985:1-60.
16. Shi H, Cenedeila RJ. Regional distribution of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and protein mass in the ocular lens. J Lipid Res. 1993; 34:2177-2182.
17. Lees MB, Paxman S. Modification of the Lowry procedure for the analysis of proteolipid protein. AnalBiochem. 1972:47:184-192.
18. Li LK, So L, Spector A. Age-dependent changes in the distribution and concentration of human lens cholesterol and phospholipids. Biochem BiophysActaAWl; 917:112-120.
19. Taylor VL, al-Ghoul KJ, Lane CW, et al. Morphology of the normal human lens. Invest Ophthalmol Vis Sei. 1996:37:1396-1410.
20. Cenedella RJ, Bierkamper GG. Mechanism of cataract production by 3-(2diethylaminoethoxy)androst-5-en-17-one hydrochloride, U18666A: an inhibitor of cholesterol biosynthesis. Exp Eye Res. 1979:28:673-688.
21. Cenedella RJ. Source of cholesterol for the ocular lens, studied with U18666A: a cataract-producing inhibitor of lipid metabolism. Exp Eye Res. 1983:37:33-43.
22. Mark M, Müller P, Maier R, Eisele B. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996:37:148-158.
23. Morand OH, Aebi JD, Dehmlow H, et al. RO 48-8071, a new 2,3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997;38: 373-390.
24. Eisele B, Budzinski R, Müller P, Maier R, Mark M. Effects of a novel 2,3oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in mo. J Lipid Res. 1997:38:564-575.
25. Seroquel (quetiapine fumarate) [package insert]. Wilmington, Del; Zeneca Pharmaceuticals:1997.